153 related articles for article (PubMed ID: 26742578)
21. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Bellone G; Novarino A; Vizio B; Brondino G; Addeo A; Prati A; Giacobino A; Campra D; Fronda GR; Ciuffreda L
Int J Oncol; 2009 Jun; 34(6):1701-15. PubMed ID: 19424589
[TBL] [Abstract][Full Text] [Related]
22. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.
Camp ER; Wang C; Little EC; Watson PM; Pirollo KF; Rait A; Cole DJ; Chang EH; Watson DK
Cancer Gene Ther; 2013 Apr; 20(4):222-8. PubMed ID: 23470564
[TBL] [Abstract][Full Text] [Related]
23. Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives.
Xu H; Shi M; Shao C; Li H; Wu J; Yu Y; Fang F; Guo Y; Xiao W
Microb Cell Fact; 2021 Jun; 20(1):115. PubMed ID: 34107983
[TBL] [Abstract][Full Text] [Related]
24. IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.
Shi Y; Dincheva-Vogel L; Ayemoba CE; Fung JP; Bergamaschi C; Pavlakis GN; Farzaneh F; Gaensler KML
Blood Adv; 2018 Nov; 2(22):3177-3192. PubMed ID: 30482760
[TBL] [Abstract][Full Text] [Related]
25. KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma.
Malaisé M; Rovira J; Renner P; Eggenhofer E; Sabet-Baktach M; Lantow M; Lang SA; Koehl GE; Farkas SA; Loss M; Agha A; Campistol JM; Schlitt HJ; Geissler EK; Kroemer A
J Immunol; 2014 Feb; 192(4):1954-61. PubMed ID: 24415778
[TBL] [Abstract][Full Text] [Related]
26. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
27. Polysaccharide from
Park HB; Hwang J; Zhang W; Go S; Kim J; Choi I; You S; Jin JO
Mar Drugs; 2020 Dec; 18(12):. PubMed ID: 33302530
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways.
Sawant A; Schafer CC; Jin TH; Zmijewski J; Tse HM; Roth J; Sun Z; Siegal GP; Thannickal VJ; Grant SC; Ponnazhagan S; Deshane JS
Cancer Res; 2013 Nov; 73(22):6609-20. PubMed ID: 24085788
[TBL] [Abstract][Full Text] [Related]
29. Soluble Interleukin IL-15Ralpha is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15.
Bulanova E; Budagian V; Duitman E; Orinska Z; Krause H; Rückert R; Reiling N; Bulfone-Paus S
J Biol Chem; 2007 May; 282(18):13167-79. PubMed ID: 17327231
[TBL] [Abstract][Full Text] [Related]
30. Antitumor mechanism of recombinant murine interleukin-12 vaccine.
Yin X; Yan X; Yang Q; Cao H; Liang H
Cancer Biother Radiopharm; 2010 Jun; 25(3):263-8. PubMed ID: 20578831
[TBL] [Abstract][Full Text] [Related]
31. Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27.
Morishima N; Owaki T; Asakawa M; Kamiya S; Mizuguchi J; Yoshimoto T
J Immunol; 2005 Aug; 175(3):1686-93. PubMed ID: 16034109
[TBL] [Abstract][Full Text] [Related]
32. Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer.
Oshikawa K; Rakhmilevich AL; Shi F; Sondel PM; Yang N; Mahvi DM
Hum Gene Ther; 2001 Jan; 12(2):149-60. PubMed ID: 11177552
[TBL] [Abstract][Full Text] [Related]
33. Intranasal Administration of
Wang Y; An EK; Kim SJ; You S; Jin JO
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638944
[TBL] [Abstract][Full Text] [Related]
34. Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer.
Chertova E; Bergamaschi C; Chertov O; Sowder R; Bear J; Roser JD; Beach RK; Lifson JD; Felber BK; Pavlakis GN
J Biol Chem; 2013 Jun; 288(25):18093-103. PubMed ID: 23649624
[TBL] [Abstract][Full Text] [Related]
35. The Sushi domain of soluble IL-15 receptor alpha is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo.
Wei Xq ; Orchardson M; Gracie JA; Leung BP; Gao Bm ; Guan H; Niedbala W; Paterson GK; McInnes IB; Liew FY
J Immunol; 2001 Jul; 167(1):277-82. PubMed ID: 11418660
[TBL] [Abstract][Full Text] [Related]
36. The roles of different forms of IL-15 in human melanoma progression.
Di Matteo S; Munari E; Fiore PF; Santopolo S; Sampaoli C; Pelosi A; Chouaib S; Tumino N; Vacca P; Mariotti FR; Ebert S; Machwirth M; Haas D; Pezzullo M; Pietra G; Grottoli M; Buart S; Mortier E; Maggi E; Moretta L; Caruana I; Azzarone B
Front Immunol; 2023; 14():1183668. PubMed ID: 37334356
[TBL] [Abstract][Full Text] [Related]
37. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-15 suppresses hepatitis B virus replication via IFN-β production in a C57BL/6 mouse model.
Yin W; Xu L; Sun R; Wei H; Tian Z
Liver Int; 2012 Sep; 32(8):1306-14. PubMed ID: 22380514
[TBL] [Abstract][Full Text] [Related]
39. Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models.
Yao B; He QM; Tian L; Xiao F; Jiang Y; Zhang R; Li G; Zhang L; Hou JM; Wang L; Cheng XC; Wen YJ; Kan B; Li J; Zhao X; Hu B; Zhou Q; Zhang L; Wei YQ
Hum Gene Ther; 2005 Sep; 16(9):1075-86. PubMed ID: 16149906
[TBL] [Abstract][Full Text] [Related]
40. IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells.
Tamzalit F; Barbieux I; Plet A; Heim J; Nedellec S; Morisseau S; Jacques Y; Mortier E
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8565-70. PubMed ID: 24912180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
